Overview of randomized clinical trials of lipid intervention for atherosclerotic cardiovascular disease.
This paper is a review of the scientific and economic (when possible) impact of 15 randomized clinical trials of lipid intervention for atherosclerotic cardiovascular disease. No effort has been made to be all-inclusive and certain smaller and first generation studies have been omitted. No effort has been made to offer detailed analyses of protocols; we have limited discussion to summaries of the salient features of each study presented. After stating the data, we introduce certain reflections and raise some of the more obvious questions that emerge.
D001161:Arteriosclerosis / Q000178:diet therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D003084:Colestipol / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D009539:Nicotinic Acids / Q000627:therapeutic use; D009821:Oils; D011897:Random Allocation; D012306:Risk; D013025:Glycine max; D003313:Zea mays
D005231:Fatty Acids, Unsaturated; D000960:Hypolipidemic Agents; D008055:Lipids; D009539:Nicotinic Acids; D009821:Oils; D002994:Clofibrate; D003084:Colestipol